by Fred Dumais | Jun 18, 2024 | News Release
MONTREAL, QUEBEC, June 18, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Mr. Al Moghaddam has been appointed to the newly created role of Chief Development Officer...
by Fred Dumais | Jun 13, 2024 | News Release
Record Q2-24 revenues of $14.1 million, up 4% over Q2-23 outpacing revenue softness in several non-core brands Q2-24 adjusted EBITDA loss of $2.5 million compared to $1.7 million for Q2-23, up 48% Total Enerzair and Atectura prescriptions for the 12 months...
by Fred Dumais | Jun 13, 2024 | News Release
Changes to respiratory business unit to generate more than $5 million in annual savings Follows previously announced cost saving measures exceeding $2 million Restructuring charges to be incurred in Q3-24 Cost reduction initiatives are aimed at improving margins,...
by Fred Dumais | Jun 4, 2024 | News Release
MONTREAL, QUEBEC , June 4, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2024 on...
by Fred Dumais | Apr 25, 2024 | News Release
MONTREAL, QUEBEC , April 25, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on...
by Fred Dumais | Apr 9, 2024 | News Release
MONTREAL, QUEBEC, April 9, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Steve Saviuk, Valeo’s Chief Executive Officer, will present and participate in one-on-one...
